FindTrial
Sign In

To evaluate the efficacy of Sarvakalpa-ghan-vati in management of non-alcoholic liver disorder.

CLINICAL EVALUATION OF THE THERAPEUTIC EFFICACY OF SARVAKALPA-GHAN-VATI IN NON-ALCOHOLIC LIVER DISORDER.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026362
Enrollment
40
Registered
2020-07-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K77- Liver disorders in diseases classified elsewhere

Interventions

Intervention1: Sarvakalpghan vati: ï?¶ Group A: Use of Sarvakalpa-Ghan-Vati 2 tablet twice daily,orally, associated with Pathyasevan and life style modification for two months Control Intervention1:

Sponsors

Patanjali Research Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients between the age group of 18-65 years will be selected. 2)Patients irrespective of sex, religion, occupation and chronicity will be selected for the study. 3)Both fresh and treated cases would be taken for the study. 4)Patients with higher LFT levels than the upper limit of normal value will be selected. 5)Patients with GRADE 1 and GRADE 2 fatty liver will be selected for the study. 6)Patient with controlled Diabetes mellitus having GRADE 1 and GRADE 2 fatty liver will be selected for the study.

Exclusion criteria

Exclusion criteria: 1)Patients aged 65 years will be excluded. 2)Pregnant or lactating women will be excluded. 3)Patients who had hepatitis B, C or other hepatic viral infection, autoimmune hepatitis and drug-induced hepatitis or alcoholic hepatitis will be excluded. 4)Patients with severe complications of the cardiovascular, renal or hematopoietic systems and mental diseases will be excluded. 5)Patients will be excluded having decompensated liver disease. 6)Patients with prolonged or a history of ascites, developed hepato-cellular carcinoma, hepatic encephalopathy, variceal bleeding will be excluded. 7)Patients with a history of using IFN or antiviral agents or corticosteroids or immunosuppressive drugs will also be excluded. 8)Patients having GRADE 3 fatty liver disease will be excluded

Design outcomes

Primary

MeasureTime frame
normalisation of LFT valuesTimepoint: 30 days—

Secondary

MeasureTime frame
Exacerbation in Signs & Symptoms.Timepoint: 30 days—

Countries

India

Contacts

Public ContactBhuvnesh Sharma

Uttarakhand AyurVed university, Gurukul College Haridwar

ayurveda.nature@gmail.com7838845357

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026